Biotechnology company INOVIO (NASDAQ:INO) announced on Thursday that its Chinese partner, ApolloBio, has reported positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia.
The trial met its predefined primary efficacy endpoint and showed an overall favourable safety and tolerability profile.
ApolloBio plans to use study results to support a future regulatory submission of VGX-3100 in China.
Under the agreement with ApolloBio, INOVIO is entitled to receive up to an aggregate of USD20m, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in specified territories. The company will receive royalty payments based on a tiered percentage of annual net sales if the product is approved for marketing.
Hyundai Bioscience says XAFTY available for Ebola and Hantavirus treatment
4basebio secures clinical supply agreement for Phase II immunotherapy trial
FDA approves MEKanistic Therapeutics' IND for MTX-531
Sino Biological launches XPressMAX Cell-Free Protein Synthesis Kit
Matter Bio submits first IND application for Lm-LLO-TT
Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM
Accro Bioscience completes USD50m Series C financing
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
SciBase research highlights Nevisense potential in age-related skin analysis
Atisama Therapeutics reports progress in Phase 1 study of RB042
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML